Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down After Earnings Miss

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKYGet Free Report)’s share price gapped down before the market opened on Friday following a weaker than expected earnings announcement. The stock had previously closed at $17.68, but opened at $15.47. Daiichi Sankyo shares last traded at $16.50, with a volume of 633 shares.

The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.02). Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS.

Analysts Set New Price Targets

DSNKY has been the topic of a number of research reports. Jefferies Financial Group cut Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday. Zacks Research raised Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. Two investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

View Our Latest Research Report on DSNKY

Daiichi Sankyo Trading Down 11.7%

The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.64 and a current ratio of 2.42. The firm has a 50-day moving average of $16.52 and a 200-day moving average of $17.74. The firm has a market capitalization of $29.99 billion, a P/E ratio of 17.13, a price-to-earnings-growth ratio of 3.10 and a beta of -0.17.

About Daiichi Sankyo

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.

See Also

Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.